MarketInOut Stock Screener Log In | Sign Up
 

Genmab A/S

CPH • Healthcare • Biotechnology • Quote as of 10/23/2026 16:59
Genmab A/S stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeCPH
Market Capitalization151,942 mln
Float56.43 mln
Earnings Date11/05/2026

EPS

81.08
Exceptional

P / E

32.73
Overvalued

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.85
Highly reliable

1-Year Forecast

2,592.46
Fairly priced

Relative Strength

96 / 100
Top performer

Business Description

Founded in Copenhagen in 1998, Genmab is a Danish biotechnology company focused on developing antibody-based treatments for cancer and other serious diseases. Its commercial portfolio includes therapies for blood cancers such as large B-cell lymphoma, multiple myeloma, and cervical cancer, among others. The company has a broad pipeline of treatments in development targeting a range of solid tumors and blood disorders, and works alongside major pharmaceutical partners including Johnson & Johnson, Pfizer, AbbVie, and Bristol Myers Squibb.

Key Fundamentals

EPS81.08
P/E32.73
ROE13.77
RPS1,051
ROIC15.81
ROA7.65
Interest Cover4.96
EBITDA, mln8,127
EV / EBITDA20.51
EV / EBIT22.16
Revenue, mln26,461
EV / Revenue6.30

Quote Details

Last 2,644.00
Change -10 (-0.38%)
Open 2,648.00
Volume 111,442
Turnover 294,652,640
Average Volume 134,331

Financial Ratios

Pre-Tax Profit Margin22
Leverage Ratio2.10
Current Ratio2.46
Price / Book3.59
Price / Cash Flow25.39
Price / Free Cash Flow26.32
Debt / Equity0.89
Price / Sales5.63
PEG Ratio1.75

Financial Strength

Altman Z-Score3.22
Piotroski F-Score 4 / 9
Beneish M-Score-3.85
Price to Intrinsic Value1.35
Price to Lynch Fair Value0.96
1-Year Target Price2,592.46
Shiller PE Ratio34.77

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.68% 96 / 100   
1 Month 16.58% 98 / 100   
2 Months 42.73% 99 / 100   
6 Months 54.53% 98 / 100   
1 Year 33.1% 72 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog